Table 4.
Demographic and baseline and endpoint characteristics of the study participants unable to reach target HbA1c stratified by FPG at endpoint (> or ≤6.1 mmol/L)
| Variables | FPG ≤6.1 mmol/L | FPG >6.1 mmol/L | P |
|---|---|---|---|
| Age (years), n | 211 | 615 | |
| Mean (SD) | 59.13 (11.22) | 57.52 (10.35) | 0.0564 |
| BMI (kg/m2), n | 211 | 615 | |
| Mean (SD) | 24.12 (3.04) | 25.76 (3.67) | <0.0001 |
| Duration of diabetes (years), n | 211 | 615 | |
| Mean (SD) | 9.32 (6.95) | 9.08 (6.34) | 0.6488 |
| Endpoint insulin glargine dose (U/day), n | 211 | 615 | |
| Mean (SD) | 16.42 (6.15) | 18.39 (6.62) | 0.0002 |
| Endpoint insulin glargine dose (U/kg/day), n | 211 | 615 | |
| Mean (SD) | 0.25 (0.09) | 0.26 (0.09) | 0.3275 |
| Baseline dose of premixed insulin (U/day), n | 211 | 615 | |
| Mean (SD) | 29.78 (9.28) | 32.33 (11.55) | 0.0013 |
| Baseline dose of premixed insulin (U/kg/day), n | 211 | 615 | |
| Mean (SD) | 0.46 (0.14) | 0.46 (0.16) | 0.7265 |
| FPG at baseline (mmol/L), n | 211 | 614 | |
| Mean (SD) | 8.01 (1.82) | 8.97 (2.25) | <0.0001 |
| FPG at endpoint (mmol/L), n | 211 | 615 | |
| Mean (SD) | 5.46 (0.57) | 8.01 (2.32) | <0.0001 |
| HbA1c at baseline (%), n | 211 | 615 | |
| Mean (SD) | 8.24 (1.05) | 8.29 (1.06) | 0.5162 |
| HbA1c at endpoint (%), n | 211 | 615 | |
| Mean (SD) | 7.60 (0.88) | 7.90 (0.89) | <0.0001 |
| 2-h PPG at baseline (mmol/L), n | 207 | 609 | |
| Mean (SD) | 11.67 (3.09) | 12.81 (3.86) | <0.0001 |
| 2-h PPG at endpoint (mmol/L), n | 211 | 611 | |
| Mean (SD) | 9.24 (2.66) | 10.89 (2.68) | <0.0001 |
A t test was used for comparing the two subgroups
BMI body mass index, FPG fasting plasma glucose, HbA 1c glycated hemoglobin, PPG postprandial glucose, OADs oral antidiabetic drugs, SD standard deviation